France Automated Microbiology Market 2015-2019 - The Level of Automation in the Microbiology Laboratory has Been Lagging Behind that of Other Major Clinical Laboratory Segments

Aug 12, 2015, 12:10 ET from Research and Markets

DUBLIN, Aug. 12, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/z7c2d2/20152019_france) has announced the addition of the "2015-2019 France Automated Microbiology Market: Molecular Diagnostics, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, Immunodiagnostics--Emerging Opportunities for Instrument and Reagent Suppliers--Competitive St" report to their offering.

2015-2019 France Automated Microbiology Market is a new analysis of major business opportunities emerging in the French automated microbiology market during the nextfive years. The report examines key trends, reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for molecular diagnostic, microbial identification, antibiotic susceptibility, blood culture, urine screening and immunodiagnostic procedures, as well as over 100 infectious disease tests by assay, application, market segment; profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.

Rationale

The level of automation in the microbiology laboratory has been lagging behind that of other major clinical laboratory segments, such as chemistry and hematology. The slow acceptance of the technology is in part due to the complexity of developing automation suitable for microbiology tests.

The introduction of automated microbiology instrumentation has been delayed by a number of intrinsic and technical problems. The diffusion of automated microbiology systems, once the technology was developed, has not matched that of other automated laboratory technologies. The acquisition of automation in microbiology has been slowed by forces less easily identifiable than the effects of various reimbursement plans. Some laboratorians still believe that current instrumentation is not the ultimate technology and expect better automation on the horizon.

The companies analyzed in the report include

  • Abbott,
  • Affymetrix,
  • Agilent Technologies,
  • Arca Biopharma,
  • Beckman Coulter/Danaher,
  • Becton Dickinson,
  • Biokit,
  • bioMerieux,
  • Bio-Rad,
  • Biotest,
  • Cepheid,
  • CellMark Forensics/LabCorp,
  • Decode Genetics, Diadexus,
  • Diamedix,
  • DiaSorin,
  • Eiken Chemical,
  • Elitech Group,
  • Enzo Biochem,
  • Exact Sciences,
  • Fujirebio,
  • Grifols,
  • Hologic/Gen-Probe,
  • Illumina,
  • ID Biomedical/GSK,
  • Kreatech/Leica,
  • Li-Cor Biosciences,
  • Lonza, Monogram Biosciences,
  • Myriad Genetics,
  • Ortho-Clinical Diagnostics,
  • Perkin Elmer/Caliper,
  • Proteome Sciences,
  • Qiagen,
  • Roche,

For more information visit http://www.researchandmarkets.com/research/z7c2d2/20152019_france

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com